Atropine

May be taken with or without food. Take w/ food or water.

Angle-closure glaucoma, narrow angle between the iris and cornea, 2nd or 3rd degree AV block, achalasia of oesophagus, paralytic ileus, severe ulcerative colitis, intestinal atony, toxic megacolon, pyloric stenosis, prostatic hypertrophy, obstructive uropathy, myasthenia gravis. Lactation (IV).

Patients with Down's syndrome, brain damage, autonomic neuropathy, increased intraocular pressure, spastic paralysis, hiatal hernia, hyperthyroidism, gastric ulcers, GERD, diarrhoea, COPD, heart failure, myocardial ischaemia, hypertension, and cardiac surgery. Patients with fever or those exposed to high ambient temperature. Hepatic and renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause confusion, dizziness or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, pulse rate, heart rate, and ECG. Check for signs and symptoms of atropine toxicity (e.g. fever, muscle fasciculations, delirium, and mental status).

Significant: Tachycardia, transient bradycardia, pulmonary oedema, urinary retention, delirium, agitation, amnesia; photophobia, blurred vision (ophthalmic). Rarely, hypertensive crisis and seizures. Cardiac disorders: Palpitations, chest pain. Eye disorders: Decreased lacrimation. Gastrointestinal disorders: Dry mouth, dysphagia, constipation, nausea, vomiting. General disorders and administration site conditions: Fever, irritability, asthenia, ataxia. Investigations: Irregular pulse, increased intraocular pressure, abnormal EEG, ECG changes. Metabolism and nutrition disorders: Increased thirst, hypokalaemia, hyperglycaemia. Nervous system disorders: Dysgeusia, restlessness, dizziness, headache. Psychiatric disorders: Confusion, hallucination, disorientation, insomnia. Renal and urinary disorders: Difficulty in micturition, urinary urgency. Respiratory, thoracic and mediastinal disorders: Dyspnoea, reduced bronchial secretion, laryngitis. Skin and subcutaneous tissue disorders: Anhidrosis, hot and dry skin, rash, dermatitis. Vascular disorders: Flushing.
Potentially Fatal: Asystole, MI, atrioventricular arrhythmia, atrial fibrillation, AV dissociation, ventricular tachycardia, respiratory depression, coma. Rarely, angioedema.

Additive antimuscarinic effect with amantadine, antiarrhythmics (e.g. disopyramide, quinidine), anticholinergics, TCA, MAOIs, antipsychotics (e.g. phenothiazine, clozapine, haloperidol), antiparkinsonian drugs, antispasmodics (e.g. domperidone), and some antihistamines (e.g. promethazine). Reduces absorption of ketoconazole and mexiletine. Antagonises therapeutic effects of synthetic choline esters (e.g. bethanechol, carbachol), anticholinesterase drugs (e.g. physostigmine, neostigmine, pyridostigmine), and cholinomimetic alkaloids (e.g. pilocarpine). May increase risk of severe constipation with opioid analgesics. Antagonises miotic actions of ophthalmic long-acting cholinergic antiglaucoma agents (e.g. echothiopate). May increase toxic effects of antimyasthenics, K citrate, K supplements. May antagonise gastrointestinal motility effects of cisapride, domperidone and metoclopramide.

Antidotes, Detoxifying Agents & Drugs Used in Substance Dependence / Antispasmodics / Mydriatic Drugs / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories / Other Cardiovascular Drugs

S01FA01 - atropine ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
A03BA01 - atropine ; Belongs to the class of belladonna alkaloids, tertiary amines. Used in the treatment of functional gastrointestinal disorders.